Dermaliq Strengthens Scientific & Medical Advisory Board with Renowned Hair Research Expert Ralf Paus MD, DSc, FRSB to Advance Alopecia Drug Development
WILMINGTON (DE), USA, February 05, 2025 / Biotech Newswire / -- Dermaliq Therapeutics, Inc. (Dermaliq) today announces that Ralf Paus, M.D., D.Sc., F.R.S.B. has joined the company’s Scientific and Medical Advisory Board.
Dermaliq is a private biopharmaceutical company dedicated to developing innovative treatments for hair follicle-related diseases. The hair follicle is a vital mini organ in human skin, responsible for producing pigmented hair shafts, but it remains challenging to effectively target with topical drugs.
Prof. Ralf Paus is an authority in clinical dermatology and expert in the biology and pathology of the hair follicle. His expertise will play a pivotal role in guiding the development of DLQ01, a precision drug that specifically targets receptors deep inside the hair follicles to effectively address alopecia and other follicle-related conditions.
“We are very pleased to welcome Prof. Ralf Paus to our Scientific and Medical Advisory Board at this exciting time. His unparalleled expertise in alopecia pathophysiology will be instrumental in guiding our clinical strategy as we advance our pipeline”, said Frank Löscher, PhD Dermaliq CEO. “Our hyliQ technology enables us to precisely target affected hair follicles and delivering a wide range of molecules to develop novel and highly effective and safe topical treatments.”
The company’s lead asset DLQ01 targets prostaglandin receptors to activate hair re-growth in Androgenetic Alopecia (AGA). Its novel, non-hormonal mode of action halts AGA progression, promotes transition of the follicle from telogen (resting) to anagen (growth), prolongs duration of anagen phase, and re-transforms miniaturized hair follicles back into large mini organs that generate thick, long scalp hair shafts. DLQ01 is designed to be the best-in-class AGA treatment in men and women.
"I am excited to collaborate with Dermaliq in advancing innovative solutions for alopecia treatment. Namely for the treatment of androgenic alopecia and alopecia areata, we urgently need better and more effective drugs but must overcome the challenge of low follicular bioavailability without damaging the hair follicle or the skin around it. I am intrigued that Dermaliq’s hyliQ® platform holds out the possibility to significantly increase the bioavailability of topically applied drugs in hair follicles and to thus primarily target these." stated Ralf Paus.
